Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026.

HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target

Eupraxia Pharmaceuticals shares are trading higher after the company announced updated Phase 1b/2a RESOLVE data showing the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis.

Eupraxia Pharmaceuticals Q2 EPS $(0.23) Beats $(0.25) Estimate

Eupraxia Pharmaceuticals (TSX:EPRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) by 8 percent. This is a 11.54 percent increase over losses of $(0.26) per share